According to Dr Rajan, GLP-1 drugs such as Ozempic is not designed for long-term weight loss, which requires a comprehensive approach. 

As slimming jabs explode in popularity, interest is growing in a potential alternative, in the form of a weight-loss supplement sometimes called “natural Ozempic”. It

According to Dr Rajan, GLP-1 drugs such as Ozempic is not designed for long-term weight loss, which requires a comprehensive approach. 

According to Dr Rajan, GLP-1 drugs such as Ozempic is not designed for long-term weight loss, which requires a comprehensive approach. 

Cutaneous adverse events associated with GLP-1 receptor agonists are uncommon but vary by agent, a study of FDA data shows. Medscape Medical News

(NaturalNews) A leading nutrition scientist proposes eggs as a key dietary tool for people stopping GLP-1 agonist drugs (like Ozempic) to help prevent the signi…

$SPY & $SPX — Weekly Market-Moving Headlines Jan 12–16, 2026 SPDR S&P 500 ETF Trust BATS:SPY TrendTao 🔮 SPY & SPX — Weekly Market-Moving Headlines

Welcome to the weekly edition of Healthcare IT Today Bonus Features. This article will be a weekly roundup of interesting stories, product announcements, new hires,

Cosmetic surgeons have turned to using a “fat filler” harvested from dead people in order to give patients new breasts, sexier buttocks and other body

Wegovy’s oral version of its injectable weight-loss drug is seeing tremendous interest, Novo Nordisk executive Dave Moore told FOX Business on Friday. Wegovy’s once-daily pill,

Bad news for all those who have been trying to make “Jabuary” a thing, said Angus Colwell in The Spectator. The launch of the world’s

This review talks about the development of incretin agonists (glucagon-like peptide-1 [GLP-1], GIP [glucose-dependent insulinotropic polypeptide], glucagon), oral formulation development approaches, and advanced drug delivery

Despite effective antiretroviral therapy (ART), many people with HIV (PWH) exhibit persistent immune activation (IA) and suffer metabolic comorbidities. We investigated whether residual HIV production

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) is one of the best performing pharma stocks in 2025. Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) announced on January 8 the selection of

The clock starts ticking the day you quit your GLP‑1 medication  Scripps News People coming off weight-loss injections risk fast weight gain  BBC Many people who come

Patients can already access the first GLP-1 obesity pill from Novo Nordisk, and a rival oral drug from Eli Lilly is slated for U.S. approval

Quick Read Lilly posted 53.9% revenue growth and 480% net income growth driven by GLP-1 drugs Mounjaro and Zepbound. Lilly’s operating margin hit 48.3% versus

Glucagon-like peptide-1 (GLP-1) receptor agonist drugs, like the popular weight-loss jabs Wegovy and Ozempic, have proven to be immensely effective. Beyond allowing patients to significantly

Medicina, Vol. 62, Pages 143: GLP-1 Receptor Agonist Exenatide Protects Against Doxorubicin-Induced Cardiotoxicity Through the SIRT1 Pathway: An Electrocardiographic, 99mTc-PYP Scintigraphic, and Biochemical Study Medicina

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) ameliorate hyperglycemia by directly stimulating insulin secretion from the pancreas. In contrast, the physiological role of short-lived endogenous GLP-1 remains

A study found people who stopped GLP-1 weight-loss drugs such as Ozempic, regained weight rapidly and faced higher risks of diabetes, high cholesterol and high

Days after hitting the market, the new pill version of Novo Nordisk’s wildly popular weight-loss drug will be available through Amazon’s online pharmacy. Amazon joins

What You Should Know – Amazon Pharmacy has officially added Novo Nordisk’s Wegovy® pill—the first and only FDA-approved oral GLP-1 for weight management—to its nationwide

These medications changed not only my appetite, but the entire way I think about food, hunger, and self-care.

Post Content

His discovery of the protein fragment GLP-1 was crucial in the development of Ozempic, Wegovy and other blockbuster obesity and diabetes treatments.

Many people eat healthy, cut sugar, and still struggle with stubborn fat, low energy, or blood sugar swings. In this video, Dr. Mandell explains why

Novo Nordisk’s (NVO) Novo Nordisk A/S Sponsored ADR Class B BATS:NVO KalaGhazi Based on a detailed technical analysis of Novo Nordisk’s (NVO) stock in the

Johnson & Johnson JNJ recently signed a landmark agreement with the Trump administration to lower drug prices in the United States. Following this deal, JNJ joins

Amylyx Pharmaceuticals Inc. has nominated AMX-0318, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist, as a development candidate for post-bariatric hypoglycemia and other rare diseases.

2025 was a tumultuous year for the global healthcare sector. For much of the year, policy uncertainty, particularly around U.S. drug pricing and trade barriers,

THE WORLD IS FLAT FAT: More than a quarter of adults worldwide could benefit from GLP-1 medications for weight loss, study finds.

One in five local areas in England still do not provide the weight loss jab tirzepatide (Mounjaro) on the NHS six months after the drug

Your AI doctor’s office is expanding. On Jan. 7, OpenAI announced that over the coming weeks, it will roll out ChatGPT Health, a dedicated tab

Health system pharmacists and clinicians are monitoring a wave of drug approvals expected throughout 2026, including first-in-class therapies and expanded uses of existing drugs with

Viking Therapeutics VKTX announced that it has completed enrolling patients in its exploratory maintenance dosing study of VK2735, the company’s dual agonist of the GLP-1 and

Biotech stocks have rallied strongly into 2026, building on the late-2025 momentum from positive clinical data, cheaper valuation, easy money policy and favorable macro conditions.

(MedPage Today) — Bariatric surgery and GLP-1 receptor agonists both reduced fat mass over 2 years of treatment, but surgery was associated with a more